These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Management of inherited von Willebrand disease in 2007. Federici AB, Mannucci PM. Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477 [Abstract] [Full Text] [Related]
5. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H. Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467 [Abstract] [Full Text] [Related]
6. Mild forms of von Willebrand disease: diagnosis and management. Federici AB. Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308 [Abstract] [Full Text] [Related]
7. Laboratory diagnosis and molecular classification of von Willebrand disease. Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Acta Haematol; 2009 Sep; 121(2-3):71-84. PubMed ID: 19506352 [Abstract] [Full Text] [Related]
8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U. Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [Abstract] [Full Text] [Related]
9. Diagnosis of inherited von Willebrand disease: a clinical perspective. Federici AB. Semin Thromb Hemost; 2006 Sep; 32(6):555-65. PubMed ID: 16977566 [Abstract] [Full Text] [Related]
10. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ. Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263 [Abstract] [Full Text] [Related]
11. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H. Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681 [Abstract] [Full Text] [Related]
12. Diagnosis and management of von Willebrand disease in Australia. Favaloro EJ, Bonar R, Favaloro J, Koutts J. Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198 [Abstract] [Full Text] [Related]
13. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study. Federici AB. Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393 [Abstract] [Full Text] [Related]
15. [Von Willebrand disease: from diagnosis to treatment]. Fressinaud E, Meyer D. Rev Prat; 2005 Dec 31; 55(20):2209-18. PubMed ID: 16519045 [Abstract] [Full Text] [Related]
16. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Blood Coagul Fibrinolysis; 2009 Mar 31; 20(2):89-100. PubMed ID: 19786936 [Abstract] [Full Text] [Related]
18. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Federici AB, Bucciarelli P, Castaman G, Baronciani L, Canciani MT, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Oliovecchio E, Iorio A, Mannucci PM. Semin Thromb Hemost; 2011 Jul 31; 37(5):511-21. PubMed ID: 22102194 [Abstract] [Full Text] [Related]